The results in this report therefore support the potential utility of the TLR7/8 ligands CL097 and CL075, the TLR7 ligand IMQ, and the TLR9 agonists CpG A, B, and C, in the treatment of cancer or other diseases in which the activation of pDCs may be desirable. Here, TLR9 is linked to cancer.